Toggle navigation
Home
Products
Dexolve
Services
Feasibility
Pipeline
News
Staff
Career
Search
Log In / Register
€
$
News
SBEBCD for FDA-Approved Cannabinoid-based Medications
News
1 February, 2016
Virio Health, LLC announced that it has entered into exclusive license and supply agreement with Ligand Pharmaceuticals, Inc. for Captisol to be used for the development of cannabinoid-based medications.
The Captisol formulations are expected to avoid the usual side effects of opioids (death from overdose and debilitating addiction) for the treatment of chronic pain.
http://vireohealth.com/2015/11/25/vireo-health-seeks-to-develop-fda-approved-cannabinoid-based-medications/
BACK TO NEWS